Day: November 4, 2022

On December 7, 2017, Kato, Taku; Sakamoto, Toshiaki; Niwa, Yasuki; Sawamoto, Daisuke; Otani, Naohito; Kanbe, Misaki published a patent.COA of Formula: C9H14N2 The title of the patent was Preparation of aromatic carboxylic acid amides having TRPM8 blocking effect. And the patent contained the following:

Disclosed are compounds I [ring A = benzene or thiophene; X1 = CR11 or nitrogen atom; R11 = H or (un)substituted alkyl; X2, X3 = independently CH or nitrogen atom; ring C = monocyclic ring; R1 = (un)substituted alkyl, (un)substituted alkanoyl, cyano, etc.; R1 is substituted on the adjacent position to the point of attachment to ring B; R2 = H, (un)substituted alkyl or halo; R3 = cyano, -Ra, -N(Rb)(Rc), etc.; Ra = (un)substituted alkyl, (un)substituted non-aromatic heterocycle-methyl-, (un)substituted alkenyl, etc.; Rb = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted cycloalkyl, etc.; Rc = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R4 = (un)substituted alkyl, (un)substituted alkanoyl, cyano, etc.; n = 0 or 1; R5 = H, (un)substituted alkyl, hydroxy, etc.; when n is 1, R4 and R5, together with ring C, may combine to form a bicyclic ring; or pharmacol. acceptable salts thereof]. For example, compound II was prepared from 5-bromo-3-fluoropyridine-2-carboxylic acid Et ester via conversion into 3-iodo-5-[2-(trifluoromethyl)phenyl]pyridine-2-carboxylic acid followed by amidation with 5-amino-2-trifluoromethylpyridine and reaction with 5-methyl-2-pyrrolidone. In TRPM8 blocking test, 361-example of I showed IC50 values (nmol/L) ranging from 0.2 to 2760, e.g., IC50 of II was 4 nmol/L. Of note, compounds I are useful for the treatment of chronic pain. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).COA of Formula: C9H14N2

The Article related to aromatic carboxylic acid amide preparation trpm8 blocker, chronic pain treatment aromatic carboxylic acid amide trpm8 blocking, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.COA of Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 17, 2016, Kato, Taku; Sakamoto, Toshiaki; Niwa, Yasuki; Sawamoto, Daisuke; Ohtani, Naohito; Kanbe, Misaki published a patent.HPLC of Formula: 39919-70-5 The title of the patent was Preparation of aromatic carboxylic acid amides having TRPM8 blocking effect. And the patent contained the following:

Disclosed are compounds I [ring A = benzene or thiophene; X1 = CR11 or nitrogen atom; R11 = H or (un)substituted alkyl; X2, X3 = independently CH or nitrogen atom; ring C = monocyclic ring; R1 = (un)substituted alkyl, (un)substituted alkanoyl, cyano, etc.; R1 is substituted on the adjacent position to the point of attachment to ring B; R2 = H, (un)substituted alkyl or halo; R3 = cyano, -Ra, -N(Rb)(Rc), etc.; Ra = (un)substituted alkyl, (un)substituted non-aromatic heterocycle-methyl-, (un)substituted alkenyl, etc.; Rb = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted cycloalkyl, etc.; Rc = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R4 = (un)substituted alkyl, (un)substituted alkanoyl, cyano, etc.; n = 0 or 1; R5 = H, (un)substituted alkyl, hydroxy, etc.; when n is 1, R4 and R5, together with ring C, may combine to form a bicyclic ring; or pharmacol. acceptable salts thereof]. For example, compound II was prepared from 5-bromo-3-fluoropyridine-2-carboxylic acid Et ester via conversion into 3-iodo-5-[2-(trifluoromethyl)phenyl]pyridine-2-carboxylic acid followed by amidation with 5-amino-2-trifluoromethylpyridine and reaction with 5-methyl-2-pyrrolidone. In TRPM8 blocking test, 361-example of I showed IC50 values (nmol/L) ranging from 0.2 to 2760, e.g., IC50 of II was 4 nmol/L. Of note, compounds I are useful for the treatment of chronic pain. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).HPLC of Formula: 39919-70-5

The Article related to aromatic carboxylic acid amide preparation trpm8 blocker, chronic pain treatment aromatic carboxylic acid amide trpm8 blocking, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 23, 2017, Watanabe, Atsushi; Sato, Yuuki; Ogura, Keiji; Tatsumi, Yoshiyuki published a patent.Synthetic Route of 25813-24-5 The title of the patent was Preparation of biaryl derivatives as antifungal agents and medicine containing them. And the patent contained the following:

Biaryl derivatives represented by general formula I (ring A, X1, X2, X3, Y, Z, R2a, R3, and Q are defined below) or salts thereof having excellent antifungal activity against Trichophyton, which is a major causative organism of superficial mycoses. Ring A, X1, X2, X3, Y, Z, Q, and R3 are defined as [ring A = each (un)substituted Ph or 5- or 6-membered heteroaryl each optionally fused to form (un)substituted condensed ring; Q = CH2, CF2, S(O), SO2, C(O), NH, or S; X1, X2, X3 = CR1 or N; Y = CH or N; Z = CR2b or N; R1 = H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; R3 = H, halo, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aralkyl]. R2a and R2b are defined as [R2a, R2b = H, halo, HO, cyano, formyl, pentafluorosulfanyl, Q1, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 alkoxy-C1-4 haloalkyl, C1-6 alkyl carbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C3-7 cycloalkyl, heterocycloalkyl, heterocycloalkyloxy, C2-6 alkenyl, C2-6 alkenyloxy, C2-6 alkenyl-C1-6 alkyl, C2-6 alkenyl-C1-6 alkoxy, C2-6 alkenyloxy-C1-4 alkoxy, C2-6 alkenyloxy-C1-4 haloalkyl, C2-6 alkenyloxy-C1-4 haloalkoxy, C2-6 alkynyl, C2-6 alkynyloxy, C2-6 alkynyl-C1-6 alkyl, C2-6 alkynyl-C1-6 alkoxy, C2-6 alkynyloxy-C1-4 alkyl, C2-6 alkynyloxy-C1-4 alkoxy, C2-6 alkynyloxy-C1-4 haloalkyl, C2-6 alkynyloxy-C1-4 haloalkoxy, NH2, C1-6 alkylthio, C1-6 haloalkylthio; ring B = each (un)substituted carbocyclic or heterocyclic ring; L = a single bond, (CH2)p, O(CH2)p, (CH2)pO, (CH2)pO(CH2)q, NRc(CH2)p , (CH2)pNRc, or (CH2)pNRc(CH2)q; p, q = 1, 2, or 3; one or a plural number of H atoms of each (CH2)p or (CH2)q is optionally substituted with halo, C1-4 alkyl, or C3-7 cycloalkyl; Rc = H or C1-6 alkyl; when Z = CR2b, R2a and R2b together with the carbon atoms to which they are bonded form each (un)substituted carbocyclic or heterocyclic ring]. The biaryl derivatives I include arylpyridine or heterocyclylpyridine derivatives, e.g. 3-phenyl-2-[(pyridin-3-yl)oxy]pyridine, 2-[(pyridin-3-yl)oxy]-3,3′-bipyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]isoquinoline, 8-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoline, 3-(2,3-dihydrobenzofuran-7-yl)-2-[(pyridin-3-yl)oxy]pyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoxaline, and 3-(chroman-8-yl)-2-[(pyridin-3-yl)oxy]pyridine derivatives Thus, etherification of 3-bromo-2-chloropyridine with 6-(trifluoromethyl)pyridin-3-ol in the presence of Cs2CO3 in DMSO with stirring at 120° for 18 h gave 76% 3-[(3-bromopyridin-2-yl)oxy]-6-(trifluoromethyl)pyridine (II). Coupling of II with 2-methoxyphenylboronic acid in the presence of bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) and Cs2CO3 in aqueous dioxane solution with stirring at 120° for 30 min under microwave irradiation gave 76% 3-(2-methoxyphenyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]pyridine (III). III showed min. inhibitory concentration of ≤0.1 μg/mL against Trichophyton mentagrophytes and T. rubrum. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Synthetic Route of 25813-24-5

The Article related to bipyridine phenylpyridine pyridylquinoline pyrimidinylpyridine heterocyclylpyridine preparation antifungal, biaryl preparation antifungal agent, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Synthetic Route of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 20, 2018, Watanabe, Atsushi; Sato, Yuki; Ogura, Keiji; Tatsumi, Yoshiyuki published a patent.Recommanded Product: 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of biaryl derivatives as antifungal agents and medicine containing them. And the patent contained the following:

Biaryl derivatives represented by general formula I (ring A, X1, X2, X3, Y, Z, R2a, R3, and Q are defined below) or salts thereof having excellent antifungal activity against Trichophyton which is a major causative organism of superficial mycoses are prepared Ring A, X1, X2, X3, Y, Z, Q, and R3 are defined as [ring A = each (un)substituted Ph or 5- or 6-membered heteroaryl each optionally fused to form (un)substituted condensed ring; Q = CH2, CF2, S(O), SO2, C(O), NH, or S; X1, X2, X3 = CR1 or N; Y = CH or N; Z = CR2b or N; R1 = H, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; R3 = H, halo, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or aralkyl]. R2a and R2b are defined as [R2a, R2b = H, halo, HO, cyano, formyl, pentafluorosulfanyl, Q1, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 alkoxy-C1-4 haloalkyl, C1-6 alkyl carbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C3-7 cycloalkyl, heterocycloalkyl, heterocycloalkyloxy, C2-6 alkenyl, C2-6 alkenyloxy, C2-6 alkenyl-C1-6 alkyl, C2-6 alkenyl-C1-6 alkoxy, C2-6 alkenyloxy-C1-4 alkoxy, C2-6 alkenyloxy-C1-4 haloalkyl, C2-6 alkenyloxy-C1-4 haloalkoxy, C2-6 alkynyl, C2-6 alkynyloxy, C2-6 alkynyl-C1-6 alkyl, C2-6 alkynyl-C1-6 alkoxy, C2-6 alkynyloxy-C1-4 alkyl, C2-6 alkynyloxy-C1-4 alkoxy, C2-6 alkynyloxy-C1-4 haloalkyl, C2-6 alkynyloxy-C1-4 haloalkoxy, NH2, C1-6 alkylthio, C1-6 haloalkylthio; ring B = each (un)substituted carbocyclic or heterocyclic ring; L = a single bond, (CH2)p, O(CH2)p, (CH2)pO, (CH2)pO(CH2)q, NRc(CH2)p , (CH2)pNRc, or (CH2)pNRc(CH2)q; p, q = 1, 2, or 3; one or a plural number of H atoms of each (CH2)p or (CH2)q is optionally substituted with halo, C1-4 alkyl, or C3-7 cycloalkyl; Rc = H or C1-6 alkyl; when Z = CR2b, R2a and R2b together with the carbon atoms to which they are bonded form each (un)substituted carbocyclic or heterocyclic ring]. The biaryl derivatives I include arylpyridine or heterocyclylpyridine derivatives, e.g. 3-phenyl-2-[(pyridin-3-yl)oxy]pyridine, 2-[(pyridin-3-yl)oxy]-3,3′-bipyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]isoquinoline, 8-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoline, 3-(2,3-dihydrobenzofuran-7-yl)-2-[(pyridin-3-yl)oxy]pyridine, 5-[2-[(pyridin-3-yl)oxy]pyridin-3-yl]quinoxaline, and 3-(chroman-8-yl)-2-[(pyridin-3-yl)oxy]pyridine derivatives Thus, etherification of 3-bromo-2-chloropyridine with 6-(trifluoromethyl)pyridin-3-ol in the presence of Cs2CO3 in DMSO with stirring at 120° for 18 h gave 76% 3-[(3-bromopyridin-2-yl)oxy]-6-(trifluoromethyl)pyridine (II). Coupling of II with 2-methoxyphenylboronic acid in the presence of bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) and Cs2CO3 in aqueous dioxane solution with stirring at 120° for 30 min under microwave irradiation gave 76% 3-(2-methoxyphenyl)-2-[[6-(trifluoromethyl)pyridin-3-yl]oxy]pyridine (III). III showed min. inhibitory concentration of ≤0.1 μg/mL against Trichophyton mentagrophytes and T. rubrum. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Recommanded Product: 3,5-Dibromo-4-methoxypyridine

The Article related to bipyridine phenylpyridine pyridylquinoline pyrimidinylpyridine heterocyclylpyridine preparation antifungal, biaryl preparation antifungal agent, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 20, 2019, Yu, Miao; Strotman, Neil A.; Savage, Scott A.; Leung, Simon; Ramirez, Antonio published an article.Reference of Pyridine-3-sulfonic acid The title of the article was A Practical and Robust Multistep Continuous Process for Manufacturing 5-Bromo-N-(tert-butyl)pyridine-3-sulfonamide. And the article contained the following:

A multistep continuous flow process involving (1) magnesium-halogen exchange, (2) sulfonylation with sulfuryl chloride, and (3) reaction with tert-butylamine was developed for the synthesis of an arylsulfonamide pharmaceutical intermediate in the synthesis of BMS-919373. The process was successfully implemented, including a robust control strategy to manage the levels of several process impurities, to produce 76 kg of 5-bromo-N-(tert-butyl)pyridine-3-sulfonamide (I). As the instability of the reactive intermediates and existence of strong exotherms made a batch process unsuitable for production beyond a 1 kg scale, the alternative continuous process led to a practical and robust manufacturing route to the active pharmaceutical ingredient. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Reference of Pyridine-3-sulfonic acid

The Article related to bromo tertbutyl pyridine sulfonamide preparation multistep continuous process, magnesium halogen exchange sulfonylation amination continuous flow, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Reference of Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 28, 2007, Glatthar, Ralf; Orain, David; Spanka, Carsten published a patent.SDS of cas: 85614-89-7 The title of the patent was Preparation of nicotinic acid derivatives as modulators of mGluR5 metabotropic glutamate receptors. And the patent contained the following:

Title compounds [I; R1 = (substituted) alkyl, PhCH2; R2 = H, (substituted) alkyl, PhCH2; R1R2N = (substituted) heterocyclyl; R3, R4 = halo, OH, alkyl, alkoxy, amino, alkylamino, dialkylamino; Q, V, W = CH, CR4, N; X = CH, N; Y = CH, CR3, N; Z = CR6aR6b, NR5, O; R5 = H, OH; R6a, R6b = H, halo, OH, amino, alkyl, alkoxy, haloalkyl; provided that Q, V, W are not all N], were prepared Thus, 6-chloro-N,N-diethylnicotinamide (preparation given) and 4-chloroaniline were heated in aqueous HOAc in a sealed vial at 100° overnight to give after chromatog. 6-(4-chlorophenylamino)-N,N-diethylnicotinamide hydrochloride. The latter at 10 μM gave 95% inhibition of mGluR5 activity. The experimental process involved the reaction of Ethyl 5-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate(cas: 85614-89-7).SDS of cas: 85614-89-7

The Article related to nicotinic acid derivative preparation mglur5 metabotropic glutamate receptor modulator, gastrointestinal nervous system urinary tract disorder treatment, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.SDS of cas: 85614-89-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Tanaka, Katsumasa; Hattori, Hiroshi; Yabe, Ryota; Nishimura, Takahiro published an article in 2022, the title of the article was Ir-Catalyzed cyclization of α,ω-dienes with an N-methyl group via two C-H activation steps.Related Products of 156267-13-9 And the article contains the following content:

Iridium-catalyzed sp3 C-H alkylation of an N-Me group with 1,5- and 1,6-dienes proceeded to give five- and six-membered carbocyclic compounds, resp., in high yields. The reaction involved intermol. alkylation of the N-Me group with a vinyl moiety and subsequent intramol. cyclization at the β-position of the initially formed alkylated intermediate. The reaction using a chiral bidentate phosphine ligand enabled the asym. synthesis of the cyclic compounds The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).Related Products of 156267-13-9

The Article related to methylpyridinamine diene iridium catalyst regioselective bond activation alkylation cyclization, cycloalkylmethylpyridinamine enantioselective preparation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Related Products of 156267-13-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2022, Gavory, Gerald; Ghandi, Mahmoud; Chicas, Agustin; Warmuth, Markus published a patent.HPLC of Formula: 39919-70-5 The title of the patent was Preparation of isoindolinone compounds for treating Myc-driven cancers with GSPT1 degraders. And the patent contained the following:

The present disclosure relates to new methods to predict the responsiveness of cancer patients to GSPT1 neg. modulators and thus determine the of efficacy GSPT1 neg. modulators to treat cancer patients by determining the level of one or more biomarkers in samples of the patients. The present disclosure also relates to applications of these methods, which includes stratifying cancer malignancies, in particular identifying Myc-driven cancers, and thereby devising optimized and personalized treatments for these cancer patients, as well as optimizing the selection of patient populations for resp. clin. trials. The title compounds I [X1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; or X1 together with X4 forms (un)substituted 4-8 membered heterocycloalkyl; X2 = H, cycloalkyl, aryl, etc.; X3 = NH, O; X4 = NH, CH2; X5 = H, alkyl, alkoxy, CN, etc.; L1 and L2 = (independently) a covalent bond, (un)substituted alkylene; L3 = a covalent bond, O, (un)substituted alkylene, etc.] or pharmaceutically acceptable salts or stereoisomers thereof, were prepared E.g., a multi-step synthesis of II, starting from Me 5-bromo-2-methylbenzoate, was described. Exemplified compounds I were tested for their ability for cereblon binding (data given for representative compounds I). The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).HPLC of Formula: 39919-70-5

The Article related to isoindolinone dioxopiperidinyl preparation cereblon modulator anticancer myc driven cancer, gspt1 degrader modulator biomaker isoindolinone dioxopiperidinyl preparation, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Deconinck, E.; Sacre, P. Y.; Baudewyns, S.; Courselle, P.; De Beer, J. published an article in 2011, the title of the article was A fast ultra high pressure liquid chromatographic method for qualification and quantification of pharmaceutical combination preparations containing paracetamol, acetyl salicylic acid and/or antihistaminics.Recommanded Product: 132-20-7 And the article contains the following content:

A fully validated UHPLC method for the identification and quantification of pharmaceutical preparations, containing paracetamol and/or acetyl salicylic acid, combined with anti-histaminics (phenylephrine, pheniramine maleate, diphenhydramine, promethazine) and/or other additives as quinine sulfate, caffeine or codeine phosphate, was developed. The proposed method uses a Waters Acquity BEH C18 column (2 mm × 100 mm, 1.7 μm) with a gradient using an ammonium acetate buffer pH 4.0 as aqueous phase and methanol as organic modifier. The obtained method was fully validated based on its measurement uncertainty (accuracy profile) and robustness tests. Calibration lines for all components were linear within the studied ranges. The relative bias and the relative standard deviations for all components were resp. smaller than 1.5% and 2%, the β-expectation tolerance limits did not exceed the acceptance limits of 10% and the relative expanded uncertainties were smaller than 5% for all of the considered components. A UHPLC method was obtained for the identification and quantification of these kind of pharmaceutical preparations, which will significantly reduce anal. times and workload for the laboratories charged with the quality control of these preparations The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).Recommanded Product: 132-20-7

The Article related to nsaid antihistaminic uplc quality control, Pharmaceutical Analysis: Synthetic Organic Compounds and other aspects.Recommanded Product: 132-20-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Sawant, Sakshi; Borkar, Nitin published an article in 2014, the title of the article was Method development of an simultaneous determination of common cough and cold ingredients by high performance liquid chromatography (HLPC) in multi component cough and cold oral drug products.Application In Synthesis of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate And the article contains the following content:

A common simultaneous HPLC method has been developed for the quantification of common analytes used in cough and cold products. The seven analytes acetaminophen, guafenesin, pheniramine maleate, phenylephrine hydrochloride, diphenhydramine, chlorpheniramine maleate, dextromethorphan are separated out. HPLC separation was achieved on a C18 column with a gradient system optimized for all seven analytes with different chem. structures. The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).Application In Synthesis of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate

The Article related to cough cold high performance liquid chromatog, Pharmaceutical Analysis: Synthetic Organic Compounds and other aspects.Application In Synthesis of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem